US Stock Market Move | Beigene (ONC.US) rose more than 3%, BTK inhibitors officially put into clinical use in China.

On Monday, Beigene (ONC.US) rose more than 3%, reaching $255.81. On the news front, Beigene announced on June 23rd that the bispecific HER2 inhibitor drug BaHeng (intravenous Zanidatuzumab) has officially entered the market in China and is being used in clinical settings across multiple medical institutions nationwide. As the first and currently only bispecific antibody approved in China for targeted therapy of HER2-high cholangiocarcinoma, the initial batch of drugs will quickly be available in hospitals and pharmacies in over a hundred cities across the country, benefiting patients with cholangiocarcinoma (BTC).